Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Lei Wang
Sinovac Life Sciences Co., Ltd.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
2
DOWNLOADS
1,277
TOTAL CITATIONS
18
Feedback
Scholarly Papers (2)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial
Number of pages: 22
Posted: 06 Apr 2021
Bihua Han
,
Yufei Song
,
Changgui Li
,
Wanqi Yang
,
Qingxia Ma
,
Zhiwei Jiang
,
Minjie Li
,
Xiaojuan Lian
,
Wenbin Jiao
, Lei Wang,
Qun Shu
,
Zhiwei Wu
,
Yuliang Zhao
,
Qi Li
and
Qiang Gao
Hebei Provincial Center for Disease Control and Prevention, Sinovac Biotech CO., Ltd., National Institutes for Food and Drug Control, Sinovac Biotech CO., Ltd., Zanhuang County Center for Disease Control and Prevention, Beijing Key Tech Statistics Technology Co., Ltd., Hebei Provincial Center for Disease Control and Prevention, Sinovac Biotech Ltd., Zanhuang County Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Beijing Key Tech Statistics Technology Co., Ltd., Hebei Provincial Center for Disease Control and Prevention, Hebei Provincial Center for Disease Control and Prevention, Hebei Provincial Center for Disease Control and Prevention and Sinovac Biotech Ltd.
Downloads
1,098
(49,627)
Citation
18
View PDF
Download
Abstract:
2.
Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial
Number of pages: 35
Posted: 03 May 2022
Lei Wang,
Zhiwei Wu
,
Zhifang Ying
,
Minjie Li
,
Yuansheng Hu
,
Qun Shu
,
Jing Li
,
Qingxia Ma
,
Hengming Zhang
,
Wenbin Jiao
,
Lin Wang
,
Yuliang Zhao
and
Qiang Gao
Sinovac Life Sciences Co., Ltd., Hebei Provincial Center for Disease Control and Prevention, National Institutes for Food and Drug Control, Hebei Provincial Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Beijing Key Tech Statistics Technology Co., Ltd., Sinovac Life Sciences Co., Ltd., Zanhuang County Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Zanhuang County Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Hebei Provincial Center for Disease Control and Prevention and Sinovac Life Sciences Co., Ltd.
Downloads
179
(422,345)
View PDF
Download
Abstract:
SARS-CoV-2, COVID-19, COVID-19 vaccine booster shot, clinical trial, children and adolescents
Feedback
